Abstract：Objective To evaluate the efficacy and adverse effects of γ-SBRT combinaed with targeted drug erlotinib on advanced stage non-small cell lung cancer. Methods Forty-two advanced stage non-small cell lung cancer patients were finally confirmed by pathohistological or cytological examination. All patients, after starting gamma knife radiosurgery, took orally targeted drugs erlotinib from August 2008 to August 2012,100-150 mg/d,1 hour before meal eating or 2 hours after meal, uninterrupted medication for at least 2 months. The efficacy and toxic reactions were evaluated after at least one month at the end of gamma knife radiosurgery. Results In 42 patients, the objective response rate reached 19.0%(8/42), the disease control rate reached 61.9% (26/42) , and the median time to disease progression was 5.2 months, the median survival time was 11.5 months. Major adverse effects were myelosuppression, lassitude and gastrointestinal tract reactions, most of which wereⅠ/Ⅱ degree with less being Ⅲ/Ⅳ degree. Conclusions The efficacy of γ-SBRT in combined with targeted drug erlotinib on advanced stage non-small cell lung cancer is acceptable and adverse effects are tolerable.
Timmerman R D, Kavanagh B D. Stereotatic body radiation therapy[J]. Curr probl Cancer, 2005, 29(3): 120-157.
[6]
von Pawel J, Wagner H, Duell T, et al. Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: two case reports. Onkologie[J], 2008, 31(3):123-126.
[3]
Martel M K. Advanced radiation treatment planning and delivery approaches for treatment of lung cancer[J]. Hematol Oncol Clin North Am, 2004, 18(1): 231-43.
[7]
Lind J S, Lagerwaard F J, Smit E F, et al. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2009, 74(5):1391-1396.
Wang M, Morsbach F, Sander D, et al. EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks[J]. Cancer Res, 2011, 71(19):6261-6269.
[6]
von Pawel J, Wagner H, Duell T, et al. Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: two case reports. Onkologie[J], 2008, 31(3):123-126.
[10]
Perez-Soler R, Chachoua A, H ammond L A, et al.Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer[J]. J Clin Oncol,2004,22(16):3238-3247.
[7]
Lind J S, Lagerwaard F J, Smit E F, et al. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2009, 74(5):1391-1396.
Wang M, Morsbach F, Sander D, et al. EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks[J]. Cancer Res, 2011, 71(19):6261-6269.
[10]
Perez-Soler R, Chachoua A, H ammond L A, et al.Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer[J]. J Clin Oncol,2004,22(16):3238-3247.
2013, Vol. 24 
